11月26日，泰恩康盘中上涨2.03%，截至13:10，报29.66元/股，成交6689.80万元，换手率0.75%，总市 值126.20亿元。 资金流向方面，主力资金净流出476.10万元，特大单买入0.00元，占比0.00%，卖出117.32万元，占比 1.75%；大单买入1346.97万元，占比20.13%，卖出1705.76万元，占比25.50%。 泰恩康今年以来股价涨100.53%，近5个交易日跌0.07%，近20日跌7.02%，近60日跌13.68%。 泰恩康所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：眼科概念、创新药、抗癌 治癌、抗癌药物、多肽药等。 截至9月30日，泰恩康股东户数1.20万，较上期增加9.32%；人均流通股25381股，较上期减少8.53%。 2025年1月-9月，泰恩康实现营业收入5.26亿元，同比减少8.13%；归母净利润3140.52万元，同比减少 73.00%。 分红方面，泰恩康A股上市后累计派现4.60亿元。近三年，累计派现3.77亿元。 责任编辑：小浪快报 资料显示，广东泰恩康医药股份有限公司位于广东省汕头市龙湖区泰山北路万吉南二街8号A幢，成立 ...

11月19日，博腾股份盘中下跌2.02%，截至13:00，报23.73元/股，成交1.02亿元，换手率0.86%，总市值 128.96亿元。 责任编辑：小浪快报 博腾股份所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：基金重仓、MSCI 中国、CRO概念、融资融券、多肽药等。 截至11月10日，博腾股份股东户数4.67万，较上期减少2.23%；人均流通股10674股，较上期增加 1.96%。2025年1月-9月，博腾股份实现营业收入25.44亿元，同比增长19.72%；归母净利润7991.54万 元，同比增长138.71%。 分红方面，博腾股份A股上市后累计派现11.93亿元。近三年，累计派现8.66亿元。 机构持仓方面，截止2025年9月30日，博腾股份十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2397.76万股，相比上期增加1321.87万股。天弘医药创新A（010654）位居第六大流通股 东，持股593.96万股，相比上期减少45.84万股。华安聚优精选混合（009714）位居第九大流通股东，持 股377.75万股，为新进股东。南方中证1000ETF（512100 ...

Core Viewpoint - 博瑞医药's stock has experienced significant fluctuations in 2023, with a year-to-date increase of 73.80% but a recent decline in the last five trading days by 1.95% [2] Group 1: Stock Performance - As of November 18, 博瑞医药's stock price is 52.32 CNY per share, with a market capitalization of 22.137 billion CNY [1] - The stock has seen a 53.20% decline over the past 60 days [2] - The trading volume on November 18 was 1.17 billion CNY, with a turnover rate of 0.52% [1] Group 2: Financial Performance - For the period from January to September 2025, 博瑞医药 reported a revenue of 874 million CNY, a year-on-year decrease of 10.50% [2] - The net profit attributable to shareholders for the same period was 50.32 million CNY, down 71.64% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, 博瑞医药 had 19,600 shareholders, an increase of 104.44% from the previous period [2] - The average number of circulating shares per shareholder decreased by 51.05% to 21,629 shares [2] - The company has distributed a total of 246 million CNY in dividends since its A-share listing, with 129 million CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 8.7219 million shares, an increase of 5.471 million shares from the previous period [3] - The ninth-largest circulating shareholder is Innovation Drug, holding 2.9109 million shares, with an increase of 98,300 shares from the previous period [3]

11月14日，博瑞医药（维权）盘中上涨2.02%，截至10:39，报55.49元/股，成交3.19亿元，换手率 1.37%，总市值234.78亿元。 资金流向方面，主力资金净流入1714.71万元，特大单买入1799.70万元，占比5.65%，卖出1781.45万 元，占比5.59%；大单买入9794.36万元，占比30.73%，卖出8097.89万元，占比25.41%。 博瑞医药今年以来股价涨84.33%，近5个交易日涨4.27%，近20日涨8.17%，近60日跌51.15%。 责任编辑：小浪快报 资料显示，博瑞生物医药(苏州)股份有限公司位于江苏省苏州工业园区星湖街218号纳米科技园C25-C28 栋,香港铜锣湾勿地臣街1号时代广场2座31楼，成立日期2001年10月26日，上市日期2019年11月8日，公 司主营业务涉及研发和生产高端仿制药和原创性新药。主营业务收入构成为：产品销售收入89.90%， 技术权益及服务收入6.77%，其他(补充)3.33%。 博瑞医药所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：仿制药、生物医药、创新 药、多肽药、中盘等。 机构持仓方面，截止2025年9月3 ...

博济医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：幽门螺杆概念、肝 炎治疗、中药、小盘、多肽药等。 11月13日，博济医药盘中上涨2.19%，截至13:09，报10.74元/股，成交1.31亿元，换手率4.45%，总市值 41.43亿元。 资金流向方面，主力资金净流出92.84万元，特大单买入523.74万元，占比4.00%，卖出629.01万元，占 比4.81%；大单买入1706.09万元，占比13.04%，卖出1693.66万元，占比12.94%。 博济医药今年以来股价涨23.19%，近5个交易日涨7.51%，近20日涨9.15%，近60日跌4.11%。 资料显示，博济医药科技股份有限公司位于广东省广州市天河区华观路1933号万科云广场A栋7楼，成 立日期2002年9月29日，上市日期2015年4月24日，公司主营业务涉及为医药企业和其他新药研发机构的 新药研发提供临床前研究服务、临床研究服务、技术成果转化服务以及与新药研发有关的其他咨询服务 等,协助客户快速、高效地完成新药研发的各个阶段。主营业务收入构成为：临床研究服务80.18%，临 床前研究服务11.31%，其他咨询服务6 ...

Core Viewpoint - Boten Co., Ltd. experienced a stock price decline of 2.02% on November 12, with a current price of 24.25 CNY per share and a total market capitalization of 13.178 billion CNY, despite a year-to-date increase of 53.77% in stock price [1] Financial Performance - For the period from January to September 2025, Boten Co., Ltd. achieved a revenue of 2.544 billion CNY, representing a year-on-year growth of 19.72%, and a net profit attributable to shareholders of 79.9154 million CNY, which is a significant increase of 138.71% [2] - The company has distributed a total of 1.193 billion CNY in dividends since its A-share listing, with 866 million CNY distributed over the past three years [3] Shareholder Information - As of October 31, 2025, the number of shareholders for Boten Co., Ltd. was 47,800, a decrease of 4.64% from the previous period, while the average number of circulating shares per person increased by 4.86% to 10,469 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 13.2187 million shares to 23.9776 million shares, and Tianhong Medical Innovation A, which reduced its holdings by 458,400 shares to 5.9396 million shares [3]

Core Viewpoint - 博瑞医药's stock has experienced significant fluctuations, with a year-to-date increase of 73.60% but a recent decline of 5.55% over the past five trading days, indicating volatility in investor sentiment and market performance [1]. Financial Performance - For the period from January to September 2025, 博瑞医药 reported a revenue of 874 million yuan, representing a year-on-year decrease of 10.50%. The net profit attributable to shareholders was 50.32 million yuan, down 71.64% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 246 million yuan, with 129 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, 博瑞医药 had 19,600 shareholders, an increase of 104.44% from the previous period. The average number of circulating shares per shareholder decreased by 51.05% to 21,629 shares [2]. - The stock's trading activity showed a net outflow of 11.19 million yuan from major funds, with significant selling pressure observed [1]. Company Overview - 博瑞医药, established on October 26, 2001, and listed on November 8, 2019, focuses on the research and production of high-end generic drugs and original new drugs. The main revenue sources are product sales (89.90%), technical rights and services (6.77%), and other income (3.33%) [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and raw materials [1].

Core Viewpoint - Aorite's stock price has shown a positive trend with an 11.95% increase year-to-date, reflecting strong financial performance and market interest in the company [2]. Company Overview - Aorite Pharmaceutical Co., Ltd. is located in the Badu Industrial Park, Tiantai County, Zhejiang Province, established on March 5, 1998, and listed on September 21, 2020 [2]. - The company's main business involves the research, production, and sales of specialty raw materials and pharmaceutical intermediates, with revenue composition as follows: 85.12% from raw materials and intermediates, 11.64% from finished drugs, 2.74% from import and export trade, and 0.50% from other sources [2]. - Aorite belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and raw material drug sector, and is associated with concepts such as small-cap stocks, raw materials, buybacks, peptide drugs, and synthetic biology [2]. Financial Performance - For the period from January to September 2025, Aorite achieved a revenue of 1.237 billion yuan, representing a year-on-year growth of 13.67%, while the net profit attributable to shareholders was 354 million yuan, up 24.58% year-on-year [2]. - As of September 30, the number of Aorite's shareholders was 11,500, a decrease of 2.17% from the previous period, with an average of 35,094 circulating shares per person, an increase of 3.92% [2]. Dividend Information - Since its A-share listing, Aorite has distributed a total of 372 million yuan in dividends, with 272 million yuan distributed over the past three years [3].

甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、生物医 药、医疗器械、多肽药、基金重仓等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股，较上期减少 17.81%。2025年1月-9月，甘李药业实现营业收入30.47亿元，同比增长35.73%；归母净利润8.18亿元， 同比增长61.32%。 11月12日，甘李药业盘中上涨2.03%，截至09:50，报65.41元/股，成交1.78亿元，换手率0.49%，总市值 390.70亿元。 资金流向方面，主力资金净流入897.83万元，特大单买入652.78万元，占比3.68%，卖出325.78万元，占 比1.83%；大单买入4254.96万元，占比23.96%，卖出3684.13万元，占比20.75%。 甘李药业今年以来股价涨51.74%，近5个交易日涨1.92%，近20日跌7.73%，近60日涨7.21%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日期2020年6月29日，公司主营业务涉及重组胰岛素类似物原料药及注射剂的研 ...

Core Viewpoint - Frontier Biopharmaceuticals has experienced fluctuations in stock performance, with a year-to-date increase of 53.79% but a recent decline of 25.21% over the past 60 days, indicating volatility in investor sentiment and market conditions [1][3]. Company Overview - Frontier Biopharmaceuticals, established on January 15, 2013, and listed on October 28, 2020, is based in Nanjing, Jiangsu Province. The company focuses on the research, development, production, and sales of innovative drugs addressing significant unmet clinical needs [2]. - The company has a patented anti-HIV drug on the market and two drugs in clinical trials, showcasing its strong R&D capabilities and competitive edge in the HIV long-acting treatment and immunotherapy sectors [2]. - The main revenue source for the company is the anti-HIV drug Aikening, which accounts for 91.29% of total revenue, while other products contribute 8.71% [2]. Financial Performance - As of September 30, 2025, the company reported a revenue of 103 million yuan, reflecting a year-on-year growth of 12.80%. However, it also recorded a net profit loss of 160 million yuan, which is an improvement of 17.39% compared to the previous year [3]. - The number of shareholders increased by 36.49% to 16,400, while the average number of circulating shares per person decreased by 26.73% to 22,783 shares [3]. - The top ten circulating shareholders include a new institutional investor, E Fund Medical Healthcare Industry Mixed A, holding 7.72 million shares [3].